论文部分内容阅读
作者观察了重组人红细胞生成素(rh-EPO)治疗10例骨髓增生异常综合征(MDS)性贫血病人的结果。其中3例为顽固性贫血(RA)、2例为顽固性环形铁粒幼红细胞性贫血(RARS),5例为顽固性原始细胞增多性贫血(RAEB)。所有病人均有严重输血依赖性,每三个月输血≥600ml。大多数病人rh-EPO 治疗开始于末次输血后的前1～2周内,每周3次皮下注射,使用3个月。最初厢量为100u/kg,治疗4周内无反应则加大至300u/kg,若4周后仍无反应,则进一步加大剂量至
The authors observed the results of recombinant human erythropoietin (rh-EPO) in 10 patients with myelodysplastic syndrome (MDS) anemia. Of these, 3 were refractory anemia (RA), 2 were refractory ring-shaped erythroblastic anemia (RARS), and 5 were refractory ascitic anemia (RAEB). All patients had severe transfusion-dependent transfusions ≥ 600ml every three months. Most patients rh-EPO treatment began within 1 to 2 weeks after the last transfusion, 3 times a week subcutaneous injection for 3 months. The initial volume of 100u / kg, no response within 4 weeks of treatment was increased to 300u / kg, if 4 weeks after no response, then further increase the dose to